$EPIX News
Last published 1y ago
- 1y agoEPIXESSA Announces Completion of Arrangement with XenoTherapeuticsPR NewswireSOUTH SAN FRANCISCO, Calif., USA and VANCOUVER, BC, Canada, Oct. 9, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company")...
- 1y agoEPIXESSA Securityholders Approve Acquisition by XenoTherapeuticsPR NewswireSOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, Oct. 6, 2025 /PRNewswire/ - ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") is pleased to...
- 1y agoEPIXESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim OrderPR NewswireESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announced Business Combination...
- 1y agoEPIXXOMAESSA Pharma Inc. Amends Agreement with XenoTherapeuticsPR NewswireESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has reached an agreement to amend its previously announced...
- 1y agoEPIXEssa Pharma Inc. to Adjourn Special Meeting to September 29, 2025PR NewswireESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that the Board of Directors of the Company has approved an adjournment of...
- 1y agoEPIXEssa Pharma Inc. Clarifies Nasdaq Due Bill Trading for Previously Announced Cash DistributionPR NewswireESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) announced on August 14, 2025 that, in connection with the Company's previously announced...
- 1y agoEPIXEssa Pharma Inc. Announces Ex-Dividend Date and Nasdaq Due Bill Trading for Previously Announced Cash DistributionPR NewswireESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with the Company's recently announced return of...
- 1y agoEPIXEssa Pharma Inc. Announces US$80 Million Cash Distribution to ShareholdersPR NewswireESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, following the Company's receipt of an order from the Supreme Court...
- 1y agoEPIXESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Approval of an Interim Order and Cash Distribution to ShareholdersPR NewswireESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that, in connection with its previously announced business combination...
- 1y agoEPIXXOMAESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash TransactionPR NewswireESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has entered into a definitive agreement (the "Business Combination ...
- 1y agoEPIXESSA Pharma Reports Financial Results for Fiscal Second Quarter Ended March 31, 2025PR NewswireCompany continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May...
- 1y agoEPIXThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit - EPIXPR NewswireThe Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during...
- 1y agoEPIXINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities
- 1y agoEPIXESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERSPR NewswireSOUTH SAN FRANCISCO, USA and VANCOUVER, Canada, March 6, 2025 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a...
- 1y agoEPIXShareholders of ESSA Pharma Inc. Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights - EPIXPR NewswireThe Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during...
- 1y agoEPIXSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their Options If you suffered
- 1y agoEPIXThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit – EPIXGlobeNewswireNEW YORK, Feb. 06, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ:EPIX). Shareholders who purchased shares of EPIX during the class period listed
- 1y agoEPIXShareholders of ESSA Pharma Inc. Should Contact The Gross Law Firm Before March 25, 2025 to Discuss Your Rights - EPIXPR NewswireThe Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ: EPIX). Shareholders who purchased shares of EPIX during...
- 1y agoEPIXThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 25, 2025 in ESSA Pharma Inc. Lawsuit – EPIXGlobeNewswireNEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of ESSA Pharma Inc. (NASDAQ:EPIX). Shareholders who purchased shares of EPIX during the class period listed
- 1y agoEPIXDEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of ESSA PharmaGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ESSA Pharma To Contact Him Directly To Discuss Their Options If you purchased or acquired securities
- 1y agoEPIXESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024PR NewswireCompany has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and...
- 2y agoEPIXESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerPR NewswireEfficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to...
- 2y agoEPIXESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO CongressPR NewswireCombination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose...
- 2y agoEPIXESSA Pharma to Present at the 2024 Cantor Global Healthcare ConferencePR NewswireSOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 11, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a...
- 2y agoEPIXESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024PR NewswireOn track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens ...
- 2y agoEPIXESSA Pharma to Present at the JonesHealthcare Seaside SummitPR NewswireSOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, July 8, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a...
- 2y agoEPIXESSA Pharma to Present at the Jefferies Global Healthcare ConferencePR NewswireSOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 30, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
- 2y agoEPIXESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2024PR NewswireCombination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in...
- 2y agoEPIXESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferencePR NewswireSOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, April 9, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
- 2y agoEPIXESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023PR NewswireCombination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in...
- 2y agoEPIXESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferencePR NewswireSOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 6, 2024 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
- 2y agoEPIXESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers SymposiumPR NewswireCombination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Phase 2...
- 2y agoEPIXESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023PR NewswirePhase 1 dose escalation complete for masofaniten (EPI-7386)/enzalutamide combination study in patients with mCRPC; compelling safety and efficacy...
- 2y agoEPIXESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare ConferencePR NewswireSOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 21, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
- 3y agoEPIXESSA Pharma to Present at the Jefferies London Healthcare ConferencePR NewswireSOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Nov. 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
- 3y agoEPIXESSA Pharma Enters into At-The-Market Equity Offering Sales AgreementPR NewswireSOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...
- 3y agoEPIXESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific RetreatPR NewswireCombination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Across all ...
- 3y agoEPIXESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the European Society of Medical Oncology 2023 CongressPR NewswireCombination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in patients with mCRPC Across all ...
- 3y agoEPIXESSA Pharma Announces Initiation of Phase 2 Study Evaluating Masofaniten (EPI-7386) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate CancerPR NewswireRecommended Phase 2 dose regimen identified as masofaniten 600mg BID combined with enzalutamide 160mg QD Phase 2 head-to-head portion of the study to commence enrollment immediately Updated Phase 1 results selected for a
- 3y agoEPIXESSA Pharma Insiders Establish Automatic Securities Disposition PlansPR NewswireSOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, Aug. 31, 2023 /CNW/ - ESSA Pharma Inc. (NASDAQ:EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel
- 3y agoEPIXESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2023PR NewswireCompletion of the Phase 1 EPI-7386 combination study with Xtandi® (enzalutamide) expected in the third calendar quarter of 2023 followed by initiation of the randomized Phase 2 part of the study Entered into
- 3y agoEPIXESSA Pharma Appoints Lauren Merendino to its Board of DirectorsPR NewswireSOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel
- 3y agoEPIXESSA Pharma to Present at 2023 Jefferies Healthcare ConferencePR NewswireSOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 1, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel
- 3y agoEPIXESSA Pharma to Present at JMP Securities Life Sciences ConferencePR NewswireSOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 11, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel
- 3y agoEPIXESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023PR NewswireEntered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored Phase 1 study of EPI-7386 combination therapies; enrollment
- 3y agoEPIXESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferencePR NewswireSOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 18, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel
- 3y agoEPIXESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate CancerPR NewswireSOUTH SAN FRANCISCO, Calif., and VANCOUVER, Canada, April 12, 2023 /CNW/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing novel
- 3y agoEPIXPBYISMMTSummit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2022Business WireEarnings Call with Management Team Scheduled for Today at 9:00am EST Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an
- 3y agoEPIXESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare ConferencePR NewswireSOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing
- 3y agoEPIXESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)PR NewswireSOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 13, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ:EPIX), a clinical-stage pharmaceutical company focused on developing